#bstockscis @BinanceCIS
While ASTSB was splitting analyst opinion, ALABB was doing the opposite🚀
Astera Labs posted Q2 revenue of $392.4M, more than double the same quarter last year — a 104% jump — and beat EPS estimates by a wide margin.
The stock popped 13% by market close. Q3 guidance came in well above what analysts were modeling: $540-560M in sales guided versus a $416.5M consensus estimate. Morgan Stanley raised its price target from $240 to $335 the same week. Susquehanna went from $230 to $275📈
Options markets had priced in roughly a 12.5% post-earnings move going into the report — the actual move landed close to that range, which is a rare case of the derivatives market actually calling it close to right.
Does a quarter this clean make ALABB a buy for you, or are you waiting for the next one to confirm the trend?
$ALABB @BinanceCIS #bStocksCIS
While ASTSB was splitting analyst opinion, ALABB was doing the opposite🚀
Astera Labs posted Q2 revenue of $392.4M, more than double the same quarter last year — a 104% jump — and beat EPS estimates by a wide margin.
The stock popped 13% by market close. Q3 guidance came in well above what analysts were modeling: $540-560M in sales guided versus a $416.5M consensus estimate. Morgan Stanley raised its price target from $240 to $335 the same week. Susquehanna went from $230 to $275📈
Options markets had priced in roughly a 12.5% post-earnings move going into the report — the actual move landed close to that range, which is a rare case of the derivatives market actually calling it close to right.
Does a quarter this clean make ALABB a buy for you, or are you waiting for the next one to confirm the trend?
$ALABB @BinanceCIS #bStocksCIS